Hematology/Oncology Pharmacy Association

Latest News

oncology pharmacist at work with patients

Advocacy

Time to Complete Oncology Pharmacist Tasks: A Joint Opinion of HOPA and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network

May 28, 2025

HOPA and the Hematology/Oncology Practice and Research Network (PRN) of the ACCP published research producing the first comprehensive consensus statements on the average time for a U.S.-based oncology pharmacist to complete common care-related tasks.

Advocacy

Together We Can Save Cancer Research - and Lives

May 27, 2025

In the past two decades, extraordinary progress has been made in the fight against cancer. However, with Congress determined to reduce federal spending, entire cancer research, prevention, and surveillance programs are on the verge of elimination.

Membership HOPA News

Powering Through Uncertainty and Doubt: My Journey as a Non-Traditional PGY2 Oncology Resident

May 14, 2025

In this essay from the most recent issue of HOPA News, Reem M. Ghandour, PharmD, BCPS, shares insights into their non-traditional path and the lessons learned along the way.

Membership

HOPA Annual Conference 2025 Reaches New Heights in Portland, Sets Attendance Record

May 12, 2025

HOPA 2025 drew 1,702 registrants to Portland, Oregon this spring, surpassing its precious record.

HOPA News Late Breaking News

Late-Breaking HOPA News: AI Integration in Pharmacy

May 07, 2025

Aracely Sosa, PharmD; Katelyn Toeniskoetter, PharmD, BCOP; and Pearl Abraham, PharmD, BCPS, BCOP, dive into the basics and beyond of AI integration in pharmacy.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Remestemcel-L-rknd

April 30, 2025

Erin Lexner, PharmD, BCPS, PGY-2 Oncology Pharmacy Resident, and Christine Barrett, PharmD, BCOP, Oncology Pharmacy Specialist - both from Mary Babb Randolph Cancer Center at West Virginia University Hospitals - write about remestemcel-L-rknd.

Explore more from HOPA

Drug Updates

Pharmacist’s Application to Practice: Repotrectinib

January 25, 2024

Christopher L. Cornett II, PharmD PGY1 Acute Care Pharmacy Resident Anne E Hitron, PharmD, MS, MBA, BCOP ,Oncology Pharmacy Specialist, Baptist Health Louisville, Louisville, Kentucky

Journal Club

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

May 04, 2024

The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously

Late Breaking News

Clinical Oncology Pharmacy Technician: Impact of a New Role on Pharmacy and Patient Metrics at a Large Academic Cancer Center

September 20, 2024

A recently published article details the impact of having an inpatient clinical oncology pharmacy technician program.

uveal melanoma with unresectable hepatic metastases

Drug Updates

Pharmacist’s Application to Practice: Hepzato Kit™

January 11, 2024

Lainey Vargo, PharmD, PGY2-Oncology Resident Katie Murto, PharmD, BCOP and Crystal Heise, PharmD, BCOP WVUH Hospitals, Morgantown, West Virginia.

Journal Club

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

October 23, 2023

Amivantamab–chemotherapy improved PFS and intracranial PFS versus chemotherapy.

Late Breaking News

Oncology Stewardship Practice in the United States: A Hematology/Oncology Pharmacy Association National Survey

November 26, 2024

A recently published survey looks to gain insight on the current landscape of oncology stewardship in the United States.

Drug Updates

Pharmacist's Application to Practice: Momelotinib

January 11, 2024

Diana Mansour, PharmD, BCOP, Clinical Pharmacy Specialist, Charles M Gallagher, PharmD, PGY2 Oncology Pharmacy Resident; Kelsea Seago, PharmD, BCOP, Clinical Pharmacy Specialist, allfrom WVUH Hospitals, write about Momelotinib.

Journal Club

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 23, 2023

First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC.

Late Breaking News

Oncology Pharmacy Staffing Survey Across Practice Settings in the United States

September 19, 2024

The results of a recently published pharmacy staffing model survey has brought new insights into oncology pharmacy operations across the country.